• Artiva Biotherapeutics is discontinuing AlloNK development, including its planned Phase 3 trial, as longer-term clinical response durability fell below its threshold.
• Two trial participants died; one event was linked to likely fludarabine neurotoxicity, while the other was assessed as unrelated to study treatment.
• No additional patients will receive AlloNK in ongoing studies; safety monitoring will continue.
• The workforce will shrink approximately 94% to preserve capital while strategic alternatives, including a potential merger, asset sale or liquidation, are evaluated.
• Preliminary, unaudited cash, cash equivalents and investments totaled approximately $319.1 million as of September 30, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artiva Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610270730PRIMZONEFULLFEED9853782) on October 27, 2026, and is solely responsible for the information contained therein.